Tachyplesin III and granulocyte-colony stimulating factor enhance the efficacy of tazobactam/piperacillin in a neutropenic mouse model of polymicrobial peritonitis

Peptides

Volumn 29, Issue 1, 2008, Pages 31-38

  Cirioni, Oscar ^a   Ghiselli, Roberto ^a   Kamysz, Wojciech ^b   Orlando, Fiorenza ^c   Silvestri, Carmela ^a   Mocchegiani, Federico ^a   Di Matteo, Fabio ^a   Kamysz, Elzbieta ^d   Riva, Alessandra ^a   Rocchi, Marco ^e   Saba, Vittorio ^a   Scalise, Giorgio ^a   Giacometti, Andrea ^a  

^a UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^b MEDICAL UNIVERSITY OF GDANSK   (Poland)

^c INRCA   (Italy)

^d UNIVERSITY OF GDA SK   (Poland)

^e UNIVERSITY OF URBINO   (Italy)

Author keywords

Antibiotics; Antimicrobial peptides; Endotoxin; Granulocyte colony stimulating factor; Sepsis; Tachyplesin III; TNF alpha

Indexed keywords

CYCLOPHOSPHAMIDE; ENDOTOXIN; GRANULOCYTE COLONY STIMULATING FACTOR; INTERLEUKIN 6; ISOTONIC SOLUTION; PIPERACILLIN PLUS TAZOBACTAM; POLYPEPTIDE ANTIBIOTIC AGENT; SODIUM CHLORIDE; TACHYLEPSIN III; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ABDOMINAL INFECTION; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACTERIAL GROWTH; CECUM; CONTROLLED STUDY; DRUG EFFICACY; LETHALITY; LIGATION; LIVER; MALE; MESENTERY LYMPH NODE; MOUSE; NONHUMAN; PERITONEUM; PRIORITY JOURNAL; PUNCTURE; SEPTIC SHOCK; SPLEEN;

ANIMALS; ANTI-BACTERIAL AGENTS; ANTIMICROBIAL CATIONIC PEPTIDES; DISEASE MODELS, ANIMAL; DNA-BINDING PROTEINS; DRUG SYNERGISM; ENTEROCOCCUS FAECALIS; ESCHERICHIA COLI; GRANULOCYTE COLONY-STIMULATING FACTOR; MALE; MICE; MICE, INBRED BALB C; MICROBIAL SENSITIVITY TESTS; NEUTROPENIA; PENICILLANIC ACID; PEPTIDES, CYCLIC; PERITONITIS; PIPERACILLIN; SURVIVAL RATE; TIME FACTORS;

ANIMALIA; BACTERIA (MICROORGANISMS); MURINAE; MUS;

EID: 37449034989     PISSN: 01969781     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.peptides.2007.10.024     Document Type: Article

References (39)

1. Alberti C., Brun-Buisson C., Burchardi H., Martin C., Goodman S., Artigas A., et al. Epidemiology of sepsis and infection in ICU patients from an international multicenter cohort study. Intensive Care Med 28 (2002) 108-121
2. Aydin S., Caylan R., Aydin K., Yulug E., Yenilmez E., and Koksal I. The influence of G-CSF addition to antibiotic treatment of experimental sepsis on pulmonary tissue. J Natl Med Assoc 97 (2005) 1489-1495
3. Baker C.C., Chaudry I.H., Gaines H.O., and Baue A.E. Evaluation of factors affecting mortality rate after sepsis induced by cecal ligation model. Surgery 94 (1983) 331-335
4. Barreda D.R., Hanington P.C., and Belosevic M. Regulation of myeloid development and function by colony-stimulating factors. Dev Comp Immunol 28 (2004) 509-554
5. Bochud P.Y., and Calandra T. Pathogenesis of sepsis: new concepts and implications for future treatment. Br Med J 326 (2003) 262-266
6. Bowdish D.M.E., Davidson D.J., Scott M.G., and Hancock R.E. Immunomodulatory activities of small host defense peptides. Antimicrob Agents Chemother 49 (2005) 1727-1732
7. Cirioni O., Giacometti A., Kamysz W., Silvestri C., Riva A., Della Vittoria A., et al. In vitro activities of the antimicrobial peptide tachyplesin III against Pseudomonas aeruginosa. Peptides 28 (2007) 747-751
8. Cirioni O., Silvestri C., Ghiselli R., Giacometti A., Orlando F., Mocchegiani F., et al. Experimental study on the efficacy of combination of α-helical antimicrobial peptides and vancomycin against Staphylococcus aureus with intermediate resistance to glycopeptides. Peptides 27 (2006) 2600-2606
9. Clinical and Laboratory Standards Institute (CLSI). Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically: approved standard M7-A6. Villanova, PA, 2003.
10. Craig W.A., Redington J., and Ebert S.C. Pharmacodynamics of amikacin in vitro and in mouse thigh and lung infections. J Antimicrob Chemother 27 Suppl. C (1991) 29-40
11. Dann S.M., and Eckmann L. Innate immune defenses in the intestinal tract. Curr Opin Gastroenterol 23 (2007) 115-120
12. Fields G.B., and Noble R.L. Solid phase peptide synthesis utilizing 9-fluorenylmethoxycarbonyl amino acids. Int J Pep Prot Res 35 (1990) 161-214
13. Giacometti A., Cirioni O., Ghiselli R., Mocchegiani F., Viticchi C., Orlando F., et al. Antiendotoxin activity of protegrin analog IB-367 alone or in combination with piperacillin in different animal models of septic shock. Peptides 24 (2003) 1747-1752
14. Giacometti A., Cirioni O., Ghiselli R., Orlando F., Kamysz W., D'Amato G., et al. Effects of pexiganan alone and combined with betalactams in experimental endotoxic shock. Peptides 26 (2005) 307-316
15. Giacometti A., Cirioni O., Kamysz W., Silvestri C., Licci A., Riva A., et al. In vitro activity of amphibian peptides alone and in combination with antimicrobial agents against multidrug-resistant pathogens isolated from surgical wound infection. Peptides 26 (2005) 2111-2116
16. Glauser M.P., Zanetti G., Baumgartner J.D., and Cohen J. Septic shock: pathogenesis. Lancet 338 (1991) 732-736
17. Gough M., Hancock R.E.W., and Kelly N.M. Antiendotoxin activity of cationic peptide antimicrobial agents. Infect Immun 64 (1996) 4922-4927
18. Hancock R.E.W. Cationic peptides: effectors in innate immunity and novel antimicrobials. Lancet Infect Dis 1 (2001) 156-164
19. Hancock R.E.W., and Sahl H.G. Antimicrobial and host-defense peptides as new anti-infective therapeutic strategies. Nat Biotechnol 24 (2006) 1551-1557
20. Hirakura Y., Kobayashi S., and Matsuzaki K. Specific interactions of the antimicrobial peptides cyclic β-sheet tachyplesin I with lipopolysaccharides. Biochim Biophys Acta 1562 (2002) 32-36
21. Hughes W.T., Armstrong D., Bodey G.P., Bow E.J., Brown A.E., Calandra T., et al. Guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 34 (2002) 730-751
22. Ichikawa Y., Pluznik D.H., and Sachs R.J. In vitro control of the development of macrophage and granulocyte colonies. Proc Natl Acad Sci USA 56 (1966) 488-495
23. Jaccard C., Troillet N., Harbarth S., Zanetti G., Aymon D., Schneider R., et al. Prospective randomized comparison of imipenem-cilastatin and piperacillin-tazobactam in nosocomial pneumonia or peritonitis. Antimicrob Agents Chemother 42 (1998) 2966-2972
24. Kioumis I.P., Kuti J.L., and Nicolau D.P. Intra-abdominal infections: considerations form the use carbapenems. Expert Opin Pharmacother 8 (2007) 167-182
25. Klastersky J. Management of fever in neutropenic patients with different risk of complications. Clin Infect Dis 39 (2004) S32-S37
26. Livermore D.M. Bacterial resistance: origins, epidemiology, and impact. Clin Infect Dis Suppl 1 (2003) S11-S23
27. Marshall J.C. The effects of granulocyte colony-stimulating factor in preclinical models of infection and acute inflammation. Shock 24 (2005) S120-S129
28. Martin G.S., Mannino D.M., Eaton S., and Moss M. The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med 348 (2003) 1546-1554
29. Matsumoto M., Matsubara S., and Yokota T. Effect of combination therapy with recombinant human granulocyte colony-stimulating factor (rG-CSF) and antibiotics in Neutropenic mice unresponsive to antibiotics alone. J Antimicrob Chemother 28 (1991) 447-453
30. McCafferty D.G., Cudic P., Yu M.K., Behenna D.C., and Kruger R. Synergy and duality in peptide antibiotic mechanisms. Curr Opin Chem Biol 3 (1999) 672-680
31. McLemore M.L., Poursine-Laurent J., and Link D.C. Increased granulocyte colony-stimulating factor responsiveness but normal resting granulopoiesis in mice carrying a targeted granulocyte colony-stimulating factor receptor mutation derived from a patient with severe congenital neutropenia. J Clin Invest 102 (1998) 483-492
32. Nakamura T., Furunaka H., Miyata T., Tokunaga F., Muta T., Iwanaga S., et al. A class of antimicrobial peptide from the hemocytes of horseshoe crab (Tachypleus tridentatus). J Biol Chem 263 (1988) 16709-16713
33. Opal S.M., and Cross A.S. The use of immunocompromised animals in sepsis research. Sepsis 2 (1999) 235-242
34. Opal S.M., and Cross A.S. The use of immunocompromised animals as models for human septic shock. Shock 24 (2005) S64-S70
35. O'Really M., Silver G.M., Greenhalgh D.G., Gamelli R.L., Davis J.H., and Hebert J.C. Treatment of intra-abdominal infections with granulocyte colony-stimulating factor. J Trauma 33 (1992) 679-682
36. Perry C.M., and Markham A. Piperacillin/tazobactam: an updated review of its use in the treatment of bacterial infections. Drugs 57 (1999) 805-843
37. Vaara M., and Porro M. Group of peptides that act synergistically with hydrophobic antibiotics against gram-negative enteric bacteria. Antimicrob Agents Chemother 40 (1996) 1801-1805
38. Villa P., Shaklee L., Meazza C., Agnello D., Ghezzi P., and Senaldi G. Granulocyte colony-stimulating factor and antibiotics in the prophylaxis of a murine model of polymicrobial peritonitis and sepsis. J Infect Dis 178 (1998) 471-477
39. Wittmann D.H., Schein A., and Condon R.E. Management of secondary peritonitis. Ann Surg 224 (1996) 10-18